We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Part A - Final decisions on matters referred to an expert advisory committee (November 2017)
1. Advisory Committee on Medicines Scheduling (ACMS #22)
1.3 Stenabolic (SR9009)
Delegate's final decision
Final decision:
The delegate's final decision is to include stenabolic and other synthetic REV-ERB agonists in Schedule 4 with an Appendix D (Part 5) entry as follows:
Schedule 4 - New Entry
# STENABOLIC (SR9009) and other synthetic REV-ERB agonists.
Appendix D, Part 5 - New Entry
STENABOLIC (SR9009) and other synthetic REV-ERB agonists.
Index - New Entry
STENABOLIC (SR9009) and other synthetic REV-ERB agonists
cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667
Schedule 4
Appendix D, Part 5
Implementation date: 1 June 2018
Reasons:
As no new evidence has been received to alter the interim decision for stenabolic and other synthetic REV-ERB agonists, the delegate has confirmed that the final decision and reasons for the final decision are identical to the interim decision.
Public submissions on the interim decision
No public submissions were received.
Interim decision
The interim decision for Stenabolic (SR9009) was published on the TGA website on 5 February 2018 at Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017 - 1.3. Stenabolic (SR9009).
Scheduling proposal
The pre-meeting scheduling proposal for cardarine was published on the TGA website on 6 September 2017 at Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACCS/ACMS meetings, November 2017.